Course of indicators of thrombin activity in the early phase of acute myocardial infarction: Effect of fibrinolytic therapy and acute percutaneous coronary angioplasty

Thrombosis and Haemostasis

Volumn 90, Issue 1, 2003, Pages 147-154

  Dempfle, Carl Erik ^a   Kaden, Jens J ^a   Haase, Karl K ^a   Borggrefe, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute myocardial infarction; D dimer; Fibrin monomer; Fibrinopeptide A; Soluble fibrin

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTIGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; FIBRIN MONOMER; FIBRINOGEN; FIBRINOLYTIC AGENT; FIBRINOPEPTIDE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SOLUBLE PLATELET GLYCOPROTEIN V; THROMBIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYTIC THERAPY; HOSPITAL ADMISSION; HUMAN; IMMUNOASSAY; IN VIVO STUDY; MEDICAL DECISION MAKING; PHOTOMETRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; THROMBOCYTE MEMBRANE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0037961256     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613611     Document Type: Article

References (31)

1. Mak KH, Lee LH, Wong A, et al. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction. Am J Cardiol 2002;89:930-6.
2. Merlini PA, Bauer KA, Oltrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995;25:203-9.
3. Nossel HL, Yudelman I, Canfield RE, et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974;54:43-53.
4. Dardik BN, Shainoff JR. Kinetic characterization of a saturable pathway for rapid clearance of circulating fibrin monomer. Blood 1985;65:680-688.
5. Hamano A, Tanaka S, Takeda Y, Umeda M, Sakata Y. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. Clin Chim Acta 2002;318:25-32.
6. Dempfle CE, Zips S, Ergul H, Heene DL. The fibrin assay comparison trial (FACT): Correlation of soluble fibrin assays with D-dimer. Thromb Haemost 2001;86:1204-9.
7. Ravanat C, Freund M, Mangin P, et al. GPV is a marker of in vivo platelet activation - Study in a rat thrombosis model. Thromb Haemost 2000;83:327-33.
8. Azorsa DO, Moog S, Ravanat C, et al. Measurement of GPV released by activated platelets using a sensitive immunocapture ELISA - Its use to follow platelet storage in transfusion. Thromb Haemost 1999;81:131-8.
9. Gaudron P, Kugler I, Hu K, Bauer W, Eilles C, Ertl G. Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: Their inter-relation and prognostic impact. J Am Coll Cardiol 2001;38:33-40.
10. Becker U, Bartl K, Wahlefeld AW. A functional photometric assay for plasma fibrinogen. Thromb Res 1984;35:475-84.
11. Dempfle CE, Dollman M, Lill H, Puzzovio D, Dessauer A, Heene DL. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': Effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN. Blood Coagul Fibrinolysis 1993;4:79-86.
12. Lill H, Spannagl M, Trauner A, et al. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo. Blood Coagul Fibrinolysis 1993;4:97-102.
13. Kario K, Matsuo T, Kabayashi H, et al. Rapid quantitative evaluation of plasma D-dimer levels in thrombotic states using an automated latex photometric immunoassay. Thromb Res 1992;66:179-89.
14. Manten A, De Winter RJ, Minnema MC, Ten Cate H, Lijmer JG, Adams R, Peters RJ, et al. Procoagulation and proinflammatory activity in acute coronary syndromes. Cardiovasc Res 1998;40:389-95.
15. Li YH, Teng JK, Tsai WC, et al. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999;33:1543-8.
16. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97:544-52.
17. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: A marker of acute coronary thrombosis. Circulation 1985;71:912-8.
18. Wilensky RL, Pyles JM, Fineberg N. Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: Lack of efficacy of locally delivered urokinase. Am Heart J 1999;138:319-25.
19. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;39:1738-44.
20. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med 2002;346:2047-52.
21. Herrmann J, Von Birgelen C, Haude M, et al. Prognostic implication of cardiac troponin T increase following stent implantation. Heart 2002;87:549-53.
22. Ragosta M, Karve M, Brezynski D, et al. Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention. Am Heart J 1999;137:250-7.
23. Lee LV, Ewald GA, McKenzie CR, Eisenberg PR. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 628-33.
24. McCarron BI, Marder VJ, Francis CW. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy. Thromb Haemost 1999;82:1722-9.
25. Hetland O, Knudsen A, Dickstein K, Nilsen DW. Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease. Blood Coagul Fibrinolysis 2002;13:301-8.
26. Kontny F, Dempfle CE, Abildgaard U. Fibrin monomer antigen: A novel marker of mortality in acute myocardial infarction. Eur Heart J 1999;20:808-12.
27. Dempfle CE, Kontny F, Abildgaard U. Predictive value of coagulation markers concerning clinical outcome 90 days after anterior myocardial infarction. Thromb Haemost 1999;81:701-4.
28. Dempfle CE, Argiriou S, Kucher K, et al. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod. Blood 2000; 96:2793-802.
29. Dempfle CE, Zips S, Ergul H, et al. The Fibrin Assay Comparison Trial (FACT): Evaluation of 23 quantitative D-dimer assays as basis for the development of D-dimer calibrators. FACT study group. Thromb Haemost 2001;85:671-8.
30. Blann AD, Lanza F, Galajda P, et al. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis - The influence of aspirin and cigarette smoking. Thromb Haemost 2001;86:777-83.
31. Jaffe AS, Lee RG, Perez JE, Geltman EM, Wilner GD, Sobel BE. Lack of elevation of platelet factor IV in plasma from patients with myocardial infarction. J Am Coll Cardiol 1984;4:653-9.